Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857454 · ClinicalTrials.gov registry record · Phase 3
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT00857454 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 71 participants.
The verdict
NCT00857454, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone MD-Lotion® (cutaneous solution) after completion of the MTE08 (NCT00702650) trial.
Interventions
- DRUG Testosterone MD-Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857454
The ClinicalTrials.gov registry entry for NCT00857454 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Testosterone MD-Lotion is the first listed.
NCT00857454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857454 about?
NCT00857454 is a clinical study titled "A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations". Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone ...
What is the current status of trial NCT00857454?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2008-10. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00857454?
The interventions under investigation include: Testosterone MD-Lotion (DRUG).
Who is sponsoring clinical trial NCT00857454?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.